Literature DB >> 19673935

Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats.

Murat Caloglu1, Vuslat Yurut-Caloglu, Gulay Durmus-Altun, Fulya Oz-Puyan, Funda Ustun, Rusen Cosar-Alas, Mert Saynak, Sule Parlar, Fatma N Turan, Cem Uzal.   

Abstract

1. The aim of the present study was to compare the protective effects of L-carnitine and amifostine against radiation-induced late nephrotoxicity using technetium-99m diethylenetriaminepentaacetic acid scintigraphy and histopathological examination. 2. Seventy-one Albino rats were randomly divided into six groups as follows: (i) AMI + RAD (n = 15), 200 mg/kg, i.p., amifostine 30 min prior to irradiation (a single dose of 9 Gy); (ii) LC + RAD (n = 15), 300 mg/kg, i.p., L-carnitine 30 min prior to irradiation; (iii) LC (n = 10), 300 mg/kg, i.p., L-carnitine 30 min prior to sham irradiation; (iv) AMI (n = 10), 200 mg/kg, i.p., amifostine 30 min prior to sham irradiation; RAD (n = 11), 1 mL/kg, i.p., normal saline 30 min prior to irradiation; and (vi) control (n = 10), 1 mL/kg, i.p., normal saline 30 min prior to sham irradiation. Scintigraphy was performed before treatment and again 6 months after treatment. Kidneys were examined by light microscopy and a histopathological scoring system was used to assess the degree of renal damage. 3. The main histopathological findings were proximal tubular damage and interstitial fibrosis. Glomerular injury was similar in all groups. Tubular degeneration and atrophy were less common in the AMI + RAD group than in the RAD group (P = 0.011 and P = 0.015, respectively), as well as in the LC + RAD group compared with the RAD group (P = 0.028 and P = 0.036, respectively). Interstitial fibrosis in the AMI + RAD and LC + RAD groups was significantly less than that in the RAD group (P = 0.015 and P = 0.015, respectively). The highest total renal injury score (9) was seen in the RAD group. On scintigraphy, there were significant differences in post-treatment time to peak count (T(max)) and time from peak count to half count (T((1/2))) values (P = 0.01 and 0.02, respectively) between groups in the right kidney. In the control and RAD groups, the T((1/2)) of the right kidney was 8 +/- 2 and 21 +/- 2 min, respectively. The T(max) values for the AMI + RAD and LC + RAD groups (2.8 +/- 0.2 and 3.2 +/- 0.2 min, respectively) were similar to those in the control group (2.5 +/- 0.3 min). 4. Based on the results of the present study, L-carnitine and amifostine have comparable and significant protective effects against radiation-induced late nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19673935     DOI: 10.1111/j.1440-1681.2008.05103.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

2.  Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats.

Authors:  Sernaz Uzunoglu; Hakan Karagol; Fulya Ozpuyan; Rusen Cosar; Irfan Cicin; Vuslat Yurutcaloglu; Bengü Denizli; Özgür Tanriverdi; Necdet Sut; Zafer Kocak
Journal:  Med Oncol       Date:  2010-12-08       Impact factor: 3.064

3.  Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

Authors:  T Aktoz; G Durmus-Altun; U Usta; N Torun; A Ergulen; I H Atakan
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

4.  L-Carnitine Protection Against Cisplatin Nephrotoxicity In Rats: Comparison with Amifostin Using Quantitative Renal Tc 99m DMSA Uptake.

Authors:  Yakup Yürekli; Perihan Unak; Ciğdem Yenisey; Türkan Ertay; Fazilet Zumrut Biber Müftüler; Emin İlker Medine
Journal:  Mol Imaging Radionucl Ther       Date:  2011-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.